Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1978 Mar;5(3):243–247. doi: 10.1111/j.1365-2125.1978.tb01631.x

Bumetanide and frusemide: a comparison of dose-response curves in healthy men.

L E Ramsay, G T McInnes, J Hettiarachchi, J Shelton, P Scott
PMCID: PMC1429271  PMID: 656269

Abstract

1 Log dose-responses for the loop diuretics bumetanide and frusemide in healthy subjects deviated significantly from parallelism as regards urine volume and sodium excretion. Ignoring the nonparallelism the best estimate of natriuretic potency (bumetanide: frusemide) was 46:1 in the bumetanide dose range 0.5-2 mg. 2 For a given natriuresis the urinary potassium excretion following bumetanide was significantly lower than that for frusemide within this dose range. 3 The data illustrate the limitations of studies comparing diuretics at a single dose level. Extrapolation of the observed log dose-response curves provides one possible explanation for the relative potency (bumetanide: frusemide) of 20:1 reported when the drugs are used at high dosage in patients with renal failure.

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allison M. E., Lindsay M. K., Kennedy A. C. Oral bumetanide in chronic renal failure. Postgrad Med J. 1975;51 (Suppl 6):47–50. [PubMed] [Google Scholar]
  2. Asbury M. J., Gatenby P. B., O'Sullivan S., Bourke E. Bumetanide: potent new "loop" diuretic. Br Med J. 1972 Jan 22;1(5794):211–213. doi: 10.1136/bmj.1.5794.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berg K. J., Tromsdal A., Wideroe T. E. Diuretic action of bumetanide in advanced chronic renal insufficiency. Eur J Clin Pharmacol. 1976 Feb 6;9(4):265–275. doi: 10.1007/BF00561659. [DOI] [PubMed] [Google Scholar]
  4. Branch R. A., Read P. R., Levine D., Elst E. V., Shelton J., Rupp W., Ramsay L. E. Furosemide and bumetanide: a study of responses in normal English and German subjects. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):538–545. doi: 10.1002/cpt1976195part1538. [DOI] [PubMed] [Google Scholar]
  5. Brogden R. N., Speight T. M., Avery G. S. Bumetanide: A preliminary report of its pharmacological properties and therapeutic efficacy in oedema. Drugs. 1975;9(1):4–18. doi: 10.2165/00003495-197509010-00002. [DOI] [PubMed] [Google Scholar]
  6. Davies D. L., Lant A. F., Millard N. R., Smith A. J., Ward J. W., Wilson G. M. Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther. 1974 Feb;15(2):141–155. doi: 10.1002/cpt1974152141. [DOI] [PubMed] [Google Scholar]
  7. Dunn F. G., Kerr I. C., McQueen M. J., Thomson R. M. Comparison of intravenous bumetanide and frusemide during open heart surgery. Postgrad Med J. 1975;51 (Suppl 6):72–76. [PubMed] [Google Scholar]
  8. FORD R. V., SPURR C. L., MOYER J. H. The problem of bioassay and comparative potency of diuretics. I. Parenteral and oral mercurial diuretics. Antibiotic Med Clin Ther (New York) 1957 Nov;4(11):708–724. [PubMed] [Google Scholar]
  9. Feit P. W. Aminobenzoic acid diuretics. 2. 4-Substituted-3-amino-5-sulfamylbenzoic acid derivatives. J Med Chem. 1971 May;14(5):432–439. doi: 10.1021/jm00287a014. [DOI] [PubMed] [Google Scholar]
  10. Frey H. H. Pharmacology of bumetanide. Postgrad Med J. 1975;51 (Suppl 6):14–18. [PubMed] [Google Scholar]
  11. GREINER T., GOLD H., BLISS C. I., GLUCK J., MARSH R., MATHES S. B., MODELL W., OTTO H., KWIT N. T., WARSHAW L. Bioassay of diuretic agents in patients with congestive failure. J Pharmacol Exp Ther. 1951 Dec;103(4):431–440. [PubMed] [Google Scholar]
  12. Lant A. F. Effects of bumetanide on cation and anion transport. Postgrad Med J. 1975;51 (Suppl 6):35–42. [PubMed] [Google Scholar]
  13. Murdoch W. R., Auld W. H. Bumetanide--acute and long term studies of a new high potency diuretic. Postgrad Med J. 1975 Jan;51(591):10–14. doi: 10.1136/pgmj.51.591.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Olesen K. H., Sigurd B., Steiness E., Leth A. Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure. Acta Med Scand. 1973 Jan-Feb;193(1-2):119–131. [PubMed] [Google Scholar]
  15. Ostergaard E. H., Magnussen M. P., Nielsen C. K., Eilertsen E., Frey H. H. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic. Arzneimittelforschung. 1972 Jan;22(1):66–72. [PubMed] [Google Scholar]
  16. Puschett J. B., Rastegar A. Comparative study of the effects of metolazone and other diuretics on potassium excretion. Clin Pharmacol Ther. 1974 Apr;15(4):398–405. [PubMed] [Google Scholar]
  17. Ramsay L., Harrison I., Shelton J., Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther. 1975 Oct;18(4):391–400. doi: 10.1002/cpt1975184391. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES